Regulation2 min read

Congress Demands IRS Tax Relief as Cannabis Rescheduling Advances

Bipartisan lawmakers urge immediate federal tax guidance for cannabis operators facing 280E restrictions as Trump administration moves forward with rescheduling.

May 28, 2026 at 7:33 PMCannabismarketcap

Congressional representatives are demanding the Internal Revenue Service provide immediate tax guidance for cannabis businesses as the Trump administration advances federal rescheduling efforts. The bipartisan push, spearheaded by Representatives Steven Horsford and Steve Cohen, addresses the crushing tax burden that has hampered cannabis operators for over a decade under Section 280E restrictions.

The timing proves critical for cannabis companies that have operated under severe tax disadvantages, paying effective rates often exceeding 70% due to their inability to claim standard business deductions. This tax treatment has compressed margins across the sector, forcing operators like Curaleaf (CURLF), Green Thumb Industries (GTBIF), and Trulieve (TCNNF) to structure operations around tax optimization rather than operational efficiency.

Rescheduling cannabis from Schedule I to Schedule III would eliminate 280E restrictions, potentially adding 20-40 percentage points to operator margins overnight. The financial impact extends beyond individual companies to the entire supply chain, as cultivators, processors, and retailers have all absorbed inflated tax costs that distort pricing and competitive dynamics across state markets.

The congressional letter underscores growing political momentum behind cannabis tax reform, even as implementation details remain unclear. The IRS faces complex questions around transition periods, retroactive applications, and coordination with state tax systems that have evolved around federal restrictions. These operational considerations will determine whether tax relief translates into immediate financial benefits or creates new compliance burdens for operators.

Investors are pricing in substantial margin expansion across cannabis equities, with many MSO stocks trading at premiums to historical valuations despite ongoing operational challenges. The congressional pressure adds political weight to rescheduling efforts, but the ultimate financial impact depends on IRS implementation speed and scope. Companies with strong balance sheets and established operations stand to benefit most from rapid tax relief, while smaller operators may struggle to capitalize on improved margins amid continued banking restrictions and interstate commerce limitations.